M T Groot

Summary

Affiliation: Erasmus University
Country: The Netherlands

Publications

  1. ncbi Costs of prostate cancer, metastatic to the bone, in the Netherlands
    M T Groot
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, Room L3 105, 3000 DR Rotterdam, The Netherlands
    Eur Urol 43:226-32. 2003
  2. ncbi [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]
    M T Groot
    Erasmus Universiteit, Institute for Medical Technology Assessment, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 147:1460-5. 2003
  3. ncbi [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]
    M T Groot
    Institute for Medical Technology Assessment, Erasmus Medisch Centrum, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 148:480-4. 2004
  4. ncbi Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia
    M van Agthoven
    Institute for Medical Technology Assessment, Department of Health Care Policy and Management, Erasmus University Rotterdam, The Netherlands
    Bone Marrow Transplant 30:243-51. 2002
  5. ncbi Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands
    M T Groot
    Erasmus Medical Centre, Institute for Medical Technology Assessment, Rotterdam, The Netherlands
    Eur J Haematol 74:194-202. 2005
  6. ncbi Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits
    C A Uyl-de Groot
    Department of Health Care Polity and Management, Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, The Netherlands
    Vaccine 23:2379-87. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Costs of prostate cancer, metastatic to the bone, in the Netherlands
    M T Groot
    Institute for Medical Technology Assessment, Erasmus University Rotterdam, PO Box 1738, Room L3 105, 3000 DR Rotterdam, The Netherlands
    Eur Urol 43:226-32. 2003
    ....
  2. ncbi [Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]
    M T Groot
    Erasmus Universiteit, Institute for Medical Technology Assessment, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 147:1460-5. 2003
    ..To determine the average cost-effectiveness ratio of treatment of patients with chronic myeloid leukaemia (CML): with first-line interferon alpha-2a (IFN) or with second-line imatinib following IFN failure...
  3. ncbi [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]
    M T Groot
    Institute for Medical Technology Assessment, Erasmus Medisch Centrum, Postbus 1738, 3000 DR Rotterdam
    Ned Tijdschr Geneeskd 148:480-4. 2004
    ....
  4. ncbi Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia
    M van Agthoven
    Institute for Medical Technology Assessment, Department of Health Care Policy and Management, Erasmus University Rotterdam, The Netherlands
    Bone Marrow Transplant 30:243-51. 2002
    ..For patients who were alive after 2 years, cumulative expenses were calculated to be Euro 103,509 (BMT), Euro 173,587 (MUD), and Euro 105,906 (PBSCT)...
  5. ncbi Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands
    M T Groot
    Erasmus Medical Centre, Institute for Medical Technology Assessment, Rotterdam, The Netherlands
    Eur J Haematol 74:194-202. 2005
    ..To determine the incremental cost-effectiveness ratio (ICER) of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) vs. CHOP plus rituximab (R-CHOP) in diffuse large B-cell lymphoma (DLBCL) patients in the Netherlands...
  6. ncbi Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits
    C A Uyl-de Groot
    Department of Health Care Polity and Management, Institute for Medical Technology Assessment, Erasmus Medical Center Rotterdam, The Netherlands
    Vaccine 23:2379-87. 2005
    ....